{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:03:04Z","timestamp":1794204184943,"version":"4.8.0"},"reference-count":38,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Else-Kr\u00f6ner-Fresenius Stiftung","award":["2020_EKFK.19"],"award-info":[{"award-number":["2020_EKFK.19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Advanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemistry for CD138 was performed for all patients who had undergone primary surgery for SGC with curative intent. Findings were validated using matrix-assisted laser desorption\/ionization mass spectrometry (MALDI-MS) imaging. Overall, 111 primary SGC and 13 lymph node metastases from salivary duct carcinomas (SaDu) were evaluated. CD138 expression was found in 60% of all SGC with differing expression across entities (p &lt; 0.01). A mean of 25.2% of the tumor cells in mucoepidermoid carcinoma (MuEp) were positive, followed by epithelial-myoepithelial carcinoma (20.9%), acinic cell carcinoma (16.0%), and SaDu (15.2%). High-\/intermediate-grade MuEp showed CD138 expression in a mean of 34.8% of tumor cells. For SaDu, lymph node metastases showed CD138 expression in a mean of 31.2% of tumor cells which correlated with CD138 expression in their primaries (p = 0.01; Spearman\u2019s \u03c1 = 0.71). MALDI-MS imaging confirmed the presence of the CD138 protein in SGC. No significant association was found between clinicopathological data, including progression-free survival (p = 0.50) and CD138 expression. CD138 is expressed in the cell membrane of different entities of SGC and SaDu lymph node metastases and therefore represents a potential target for CD138 targeting drugs.<\/jats:p>","DOI":"10.3390\/ijms23169037","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T01:47:21Z","timestamp":1660528041000},"page":"9037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target"],"prefix":"10.3390","volume":"23","author":[{"given":"Marcel","family":"Mayer","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nachtsheim","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6872-924X","authenticated-orcid":false,"given":"Franziska","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, Germany"},{"name":"Department of Otorhinolaryngology, MALDI Imaging and Innovative Biophotonics, Jena University Hospital, Friedrich-Schiller-University, 07743 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8062-6999","authenticated-orcid":false,"given":"Ferdinand","family":"von Eggeling","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, Germany"},{"name":"Department of Otorhinolaryngology, MALDI Imaging and Innovative Biophotonics, Jena University Hospital, Friedrich-Schiller-University, 07743 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-0784","authenticated-orcid":false,"given":"Orlando","family":"Guntinas-Lichius","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Prinz","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-7954","authenticated-orcid":false,"given":"Jens Peter","family":"Klu\u00dfmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[{"name":"Medical Faculty, Institute of Pathology, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Arolt","sequence":"additional","affiliation":[{"name":"Medical Faculty, Institute of Pathology, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9019-2840","authenticated-orcid":false,"given":"Philipp","family":"Wolber","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ijc.20740","article-title":"Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database","volume":"114","author":"Carvalho","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0360-3016(86)90314-7","article-title":"Malignant salivary gland tumors","volume":"12","author":"Fitzpatrick","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_3","unstructured":"El-Naggar, A.K., Chan, J.K., Grandis, J.R., Takata, T., and Slootweg, P.J. (2017). WHO Classification of Head and Neck Tumours: International Agency for Research on Cancer, International Agency for Research on Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archotol.130.2.174","article-title":"Prognostic factors in head and neck mucoepidermoid carcinoma","volume":"130","author":"Pires","year":"2004","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1002\/hed.24107","article-title":"Salivary duct carcinoma: Treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of Salivary Gland Malignancy: ASCO Guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41199-016-0011-z","article-title":"Systemic therapy for recurrent or metastatic salivary gland malignancies","volume":"1","author":"Chintakuntlawar","year":"2016","journal-title":"Cancers Head Neck"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_10","unstructured":"Le, X.B.C., and Baumann, J. (2021, January 22\u201325). Efficacy and safety of larotrectinib in patients with advanced TRK fusion salivary gland cancer. Proceedings of the 10th American Head & Neck Society International Conference on Head and Neck Cancer, Abstract S030, Chicago, IL, USA."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12105-021-01325-5","article-title":"Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target","volume":"15","author":"Wolber","year":"2021","journal-title":"Head Neck Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e5964","DOI":"10.1097\/MD.0000000000005964","article-title":"Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern china: A 25-year retrospective study","volume":"96","author":"Ouyang","year":"2017","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.12.003","article-title":"Advances in the molecular functions of syndecan-1 (SDC1\/CD138) in the pathogenesis of malignancies","volume":"94","author":"Gharbaran","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100312","DOI":"10.1016\/j.ctarc.2021.100312","article-title":"Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance","volume":"27","author":"Czarnowski","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fonc.2013.00310","article-title":"The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors","volume":"3","author":"Szatmari","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/febs.12134","article-title":"Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alphaVbeta3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis","volume":"280","author":"Rapraeger","year":"2013","journal-title":"FEBS J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1074\/jbc.M113.541573","article-title":"Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow","volume":"289","author":"Voyvodic","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00441-009-0829-3","article-title":"Syndecans as receptors and organizers of the extracellular matrix","volume":"339","author":"Xian","year":"2010","journal-title":"Cell. Tissue Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"796052","DOI":"10.1155\/2015\/796052","article-title":"Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication","volume":"2015","author":"Szatmari","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/sj.leu.2402875","article-title":"The hepatocyte growth factor\/Met pathway controls proliferation and apoptosis in multiple myeloma","volume":"17","author":"Derksen","year":"2003","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4928315","DOI":"10.1155\/2019\/4928315","article-title":"Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues","volume":"2019","author":"Kind","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/03009742.2021.1923162","article-title":"Increased salivary syndecan-1 level is associated with salivary gland function and inflammation in patients with Sjogren\u2019s syndrome","volume":"51","author":"Lee","year":"2022","journal-title":"Scand. J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2141.1996.d01-1811.x","article-title":"A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1","volume":"94","author":"Wijdenes","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11095-018-2400-y","article-title":"Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models","volume":"35","author":"Schonfeld","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bjorl.2019.07.006","article-title":"Stromal and epithelial syndecan-1 expression in benign and malignant salivary gland tumors: Which is more reflective of behavior?","volume":"87","author":"Alaeddini","year":"2021","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10120-018-00923-7","article-title":"Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric\/gastroesophageal junction cancer","volume":"22","author":"Shah","year":"2019","journal-title":"Gastric Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Couchman, J.R. (2021). Syndecan-1 (CD138), Carcinomas and EMT. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084227"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-020-00378-z","article-title":"VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo","volume":"10","author":"Yu","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: A multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00432-006-0090-z","article-title":"Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations","volume":"132","author":"Anttonen","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bjc.1994.300","article-title":"Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck","volume":"70","author":"Inki","year":"1994","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumours, John Wiley & Sons.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00405-019-05454-0","article-title":"Parotid salivary duct carcinoma: A single institution\u2019s 20-year experience","volume":"276","author":"Stodulski","year":"2019","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ng.3096","article-title":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","volume":"46","author":"Weinreb","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3390\/cancers12092466","article-title":"Expression Profiling of Extracellular Matrix Genes Reveals Global and Entity-Specific Characteristics in Adenoid Cystic, Mucoepidermoid and Salivary Duct Carcinomas","volume":"12","author":"Arolt","year":"2020","journal-title":"Cancers"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:59Z","timestamp":1760141279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":38,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23169037"],"URL":"https:\/\/doi.org\/10.3390\/ijms23169037","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}